A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety of Atogepant in Pediatric Subjects 6 to 17 Years of Age With Episodic Migraine
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Atogepant (Primary)
- Indications Migraine with aura; Migraine without aura
- Focus Adverse reactions; Registrational
- Sponsors AbbVie
Most Recent Events
- 12 Jul 2024 Planned number of patients changed from 250 to 650.
- 12 Jul 2024 Planned End Date changed from 16 Nov 2029 to 15 Nov 2029.
- 12 Jul 2024 Planned primary completion date changed from 16 Nov 2029 to 15 Nov 2029.